Obe-cel for Multiple Sclerosis

(BOBCAT Trial)

This trial tests a new treatment called obe-cel, a type of cell therapy, to determine its safety and effectiveness for individuals with progressive multiple sclerosis (MS) unresponsive to other treatments. Participants will receive a single infusion of obe-cel following a brief chemotherapy course to prepare their bodies. The trial aims to identify any side effects and early signs of success with obe-cel. It is suitable for adults diagnosed with progressive MS who have tried at least two different therapies without success. Researchers will closely monitor participants for safety and effectiveness for up to two years. As a Phase 1 trial, this research focuses on understanding how obe-cel works in people, offering participants the opportunity to be among the first to receive this innovative treatment.

The trial information does not specify if you need to stop your current medications, but it mentions that any medications prohibited by the protocol are not allowed. It's best to discuss your current medications with the trial team to see if they are allowed.

Research has shown that obe-cel, a treatment under study for multiple sclerosis (MS), has promising safety results from other research. Specifically, early results from a study on severe lupus indicated that obe-cel is generally well-tolerated. Patients experienced fewer side effects, such as CRS (a type of immune response) and ICANS (a neurological side effect), compared to another similar treatment used for blood cancers.

Obecabtagene autoleucel (obe-cel) is unique because it uses a novel approach called CAR-T cell therapy, which modifies a patient's own immune cells to better recognize and attack the disease. Unlike traditional treatments for multiple sclerosis, which often focus on managing symptoms or slowing down the disease progression, obe-cel works by potentially providing a more targeted attack on the underlying immune dysfunction. Researchers are excited about obe-cel because this targeted approach could offer a new level of precision in treatment, potentially leading to more effective and longer-lasting results for patients.

Studies have shown that obe-cel, a treatment targeting specific cells, has been effective in conditions like relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). In these cases, it led to lasting improvements and high rates of complete recovery. Although B-ALL differs from multiple sclerosis (MS), the success in B-ALL suggests that obe-cel might also help treat MS. Obe-cel targets certain immune system cells, potentially managing MS symptoms by reducing harmful immune activity. Early results from ongoing research in MS are exploring this possibility.¹²³⁴⁶